ESEric A. Sherman

Eric A. Sherman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric A. Sherman has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry

    by Mary Jane Drake, Benjamin Brennan, Kenneth Briley Jr, Stephen M. Bart, Eric Sherman, Agnieszka M. Szemiel, Madeleine Minutillo, Frederic D. Bushman, Paul Bates

    A novel bunyavirus was recently found to cause severe febrile illness with high mortality in agricultural regions of China, Japan, and South Korea. This virus, named severe fever with thrombocytopenia syndrome virus (SFTSV), represents a new group within the Phlebovirus genus of the Bunyaviridae. Little is known about the viral entry requirements beyond showing dependence on dynamin and endosomal acidification. A haploid forward genetic screen was performed to identify host cell requirements for SFTSV entry. The screen identified dependence on glucosylceramide synthase (ugcg), the enzyme responsible for initiating de novo glycosphingolipid biosynthesis. Genetic and pharmacological approaches confirmed that UGCG expression and enzymatic activity were required for efficient SFTSV entry. Furthermore, inhibition of UGCG affected a post-internalization stage of SFTSV entry, leading to the accumulation of virus particles in enlarged cytoplasmic structures, suggesting impaired trafficking and/or fusion of viral and host membranes. These findings specify a role for glucosylceramide in SFTSV entry and provide a novel target for antiviral therapies. As obligate, intracellular parasites, viruses depend upon numerous host-derived factors to replicate. For many bunyaviruses, these pro-viral host factors are largely uncharacterized. In the present study, we used an unbiased genetic screening strategy to identify human genes that facilitate the entry process of a newly discovered pathogenic bunyavirus, severe fever with thrombocytopenia syndrome virus (SFTSV). Our screen and subsequent validation confirmed a role for the glucose-modified lipid, glucosylceramide (GlcCer), in the entry of SFTSV. We found that depletion of GlcCer in the cell leads to the accumulation of virus particles in membranous compartments, suggesting that the virions cannot properly access the cytoplasm to initiate replication. Clinically available compounds that target GlcCer formation may provide a novel antiviral therapeutic strategy for this newly emerged virus.


  • Open Access

    INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions

    by Charles C. Berry, Christopher Nobles, Emmanuelle Six, Yinghua Wu, Nirav Malani, Eric Sherman, Anatoly Dryga, John K. Everett, Frances Male, Aubrey Bailey, et al.


  • Open Access

    INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes

    by Eric Sherman, Christopher Nobles, Charles C. Berry, Emmanuelle Six, Yinghua Wu, Anatoly Dryga, Nirav Malani, Frances Male, Shantan Reddy, Aubrey Bailey, et al.


  • Top Cited Papers
    Open Access

    Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome

    by Salima Hacein-Bey Abina, H. Bobby Gaspar, Johanna Blondeau, Laure Caccavelli, Sabine Charrier, Karen Buckland, Capucine Picard, Emmanuelle Six, Nourredine Himoudi, Kimberly Gilmour, et al.

    Wiskott-Aldrich syndrome (WAS) (OMIM 301000) is a complex X-linked primary immunodeficiency caused by loss-of-function mutations in the WAS gene. The condition affects the immunohematopoietic system and has a broad spectrum of severity.1 The WAS protein (WASp) is a key regulator of the actin cytoskeleton in all hematopoietic lineages.2 WASp deficiency causes characteristic microthrombocytopenia and lymphoid and myeloid cell dysfunction, the severity of which is usually correlated with WASp expression levels. A clinical scoring system is used to stratify disease severity.3 Patients with a score from 3 to 5 display a WAS phenotype characterized by a tendency to bleed, persistent eczema, susceptibility to severe opportunistic bacterial and viral infections, autoimmune and inflammatory complications, and an elevated risk of lymphoid malignancies.3-5 In the absence of definitive treatment, patients with classic WAS do not survive beyond their second or third decade of life. Although hematopoietic stem cell (HSC) transplantation is usually curative, the use of partially HLA antigen–matched HSCs is associated with a high incidence of complications.6-10 Gene therapy based on transplantation of autologous, gene-corrected HSCs may be an effective and potentially safer alternative.


  • Top Cited Papers

    A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency

    by Salima Hacein-Bey-Abina, Sung-Yun Pai, H. Bobby Gaspar, Myriam Armant, Charles C. Berry, Stephane Blanche, Jack Bleesing, Johanna Blondeau, Helen de Boer, Karen F. Buckland, et al.

    In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus–based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). All patients received bone marrow–derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.)


  • A homozygous SLITRK6 nonsense mutation is associated with progressive auditory neuropathy in humans

    by Thierry Morlet, Mindy R. Rabinowitz, Liesl R. Looney, Tammy Riegner, L. Ashleigh Greenwood, Eric A. Sherman, Nathan Achilly, Anni Zhu, Estelle Yoo, Robert C. O'REilly, et al.

    Objectives/Hypothesis: SLITRK family proteins control neurite outgrowth and regulate synaptic development. In mice, Slitrk6 plays a role in the survival and innervation of sensory neurons in the inner ear, vestibular apparatus, and retina, and also influences axial eye length. We provide the first detailed description of the auditory phenotype in humans with recessive SLITRK6 deficiency.Study Design: Prospective observational case study.Methods: Nine closely related Amish subjects from an endogamous Amish community of Pennsylvania underwent audiologic and vestibular testing. Single nucleotide polymorphism microarrays were used to map the chromosome locus, and Sanger sequencing or high‐resolution melt analysis were used to confirm the allelic variant.Results: All nine subjects were homozygous for a novel nonsense variant of SLITRK6 (c.1240C>T, p.Gln414Ter). Adult patients had high myopia. The 4 oldest SLITRK6 c.1240C>T homozygotes had absent ipsilateral middle ear muscle reflexes (MEMRs). Distortion product otoacoustic emissions (DPOAEs) were absent in all ears tested and the cochlear microphonic (CM) was increased in amplitude and duration in young patients and absent in the two oldest subjects. Auditory brainstem responses (ABRs) were dys‐synchronised bilaterally with no reproducible waves I, III, or V at high intensities. Hearing loss and speech reception thresholds deteriorated symmetrically with age, which resulted in severe‐to‐profound hearing impairment by early adulthood. Vestibular evoked myogenic potentials were normal in three ears and absent in one.Conclusion: Homozygous SLITRK6 c.1240C>T (p.Gln414Ter) nonsense mutations are associated with high myopia, cochlear dysfunction attributed to outer hair cell disease, and progressive auditory neuropathy.Level of Evidence: N/A. Laryngoscope, 124:E95–E103, 2014


  • Open Access

    The Embryonic Transcriptome of the Red-Eared Slider Turtle (Trachemys scripta)

    by Nicholas J. Kaplinsky, Scott F. Gilbert, Judith Cebra-Thomas, Kersti Lilleväli, Merly Saare, Eric Y. Chang, Hannah E. Edelman, Melissa A. Frick, Yin Guan, Rebecca M. Hammond, et al.

    The bony shell of the turtle is an evolutionary novelty not found in any other group of animals, however, research into its formation has suggested that it has evolved through modification of conserved developmental mechanisms. Although these mechanisms have been extensively characterized in model organisms, the tools for characterizing them in non-model organisms such as turtles have been limited by a lack of genomic resources. We have used a next generation sequencing approach to generate and assemble a transcriptome from stage 14 and 17 Trachemys scripta embryos, stages during which important events in shell development are known to take place. The transcriptome consists of 231,876 sequences with an N50 of 1,166 bp. GO terms and EC codes were assigned to the 61,643 unique predicted proteins identified in the transcriptome sequences. All major GO categories and metabolic pathways are represented in the transcriptome. Transcriptome sequences were used to amplify several cDNA fragments designed for use as RNA in situ probes. One of these, BMP5, was hybridized to a T. scripta embryo and exhibits both conserved and novel expression patterns. The transcriptome sequences should be of broad use for understanding the evolution and development of the turtle shell and for annotating any future T. scripta genome sequences.


  • A homozygous missense mutation inHERC2associated with global developmental delay and autism spectrum disorder

    by Erik G. Puffenberger, Robert N. Jinks, Heng Wang, Baozhong Xin, Christopher Fiorentini, Eric A. Sherman, Dominick Degrazio, Calvin Shaw, Carrie Sougnez, Kristian Cibulskis, et al.

    We studied a unique phenotype of cognitive delay, autistic behavior, and gait instability segregating in three separate sibships. We initiated genome-wide mapping in two sibships using Affymetrix 10K SNP Mapping Arrays and identified a homozygous 8.2 Mb region on chromosome 15 common to five affected children. We used exome sequencing of two affected children to assess coding sequence variants within the mapped interval. Four novel homozygous exome variants were shared between the two patients; however, only two variants localized to the mapped interval on chromosome 15. A third sibship in an Ohio Amish deme narrowed the mapped interval to 2.6 Mb and excluded one of the two novel homozygous exome variants. The remaining variant, a missense change in HERC2 (c.1781C>T, p.Pro594Leu), occurs in a highly conserved proline residue within an RCC1-like functional domain. Functional studies of truncated HERC2 in adherent retinal pigment epithelium cells suggest that the p.Pro594Leu variant induces protein aggregation and leads to decreased HERC2 abundance. The phenotypic correlation with the mouse Herc1 and Herc2 mutants as well as the phenotypic overlap with Angelman syndrome provide further evidence that pathogenic changes in HERC2 are associated with nonsyndromic intellectual disability, autism, and gait disturbance. Hum Mutat 33:1639–1646, 2012.


  • Open Access

    Genetic Mapping and Exome Sequencing Identify Variants Associated with Five Novel Diseases

    by Erik G. Puffenberger, Robert N. Jinks, Carrie Sougnez, Kristian Cibulskis, Rebecca A. Willert, Nathan P. Achilly, Ryan P. Cassidy, Christopher J. Fiorentini, Kory F. Heiken, Johnny J. Lawrence, et al.

    The Clinic for Special Children (CSC) has integrated biochemical and molecular methods into a rural pediatric practice serving Old Order Amish and Mennonite (Plain) children. Among the Plain people, we have used single nucleotide polymorphism (SNP) microarrays to genetically map recessive disorders to large autozygous haplotype blocks (mean = 4.4 Mb) that contain many genes (mean = 79). For some, uninformative mapping or large gene lists preclude disease-gene identification by Sanger sequencing. Seven such conditions were selected for exome sequencing at the Broad Institute; all had been previously mapped at the CSC using low density SNP microarrays coupled with autozygosity and linkage analyses. Using between 1 and 5 patient samples per disorder, we identified sequence variants in the known disease-causing genes SLC6A3 and FLVCR1, and present evidence to strongly support the pathogenicity of variants identified in TUBGCP6, BRAT1, SNIP1, CRADD, and HARS. Our results reveal the power of coupling new genotyping technologies to population-specific genetic knowledge and robust clinical data.


  • Human ITCH E3 Ubiquitin Ligase Deficiency Causes Syndromic Multisystem Autoimmune Disease

    by Naomi J. Lohr, Jean P. Molleston, Kevin A. Strauss, Wilfredo Torres-Martinez, Eric A. Sherman, Robert H. Squires, Nicholas L. Rider, Kudakwashe R. Chikwava, Oscar W. Cummings, D. Holmes Morton, et al.